Deadly genetic heart condition leads Sanofi to $200M MyoKardia deal

Startup MyoKardia Inc.’s focus on treatments for deadly genetic heart diseases has landed a potential $200 million collaboration with French drug maker Sanofi...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.